The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1297
ISSUE1297
October 20, 2008
Certolizumab (Cimzia) for Crohn's Disease
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Certolizumab (Cimzia) for Crohn's Disease
October 20, 2008 (Issue: 1297)
The FDA has approved the marketing of certolizumab pegol (Cimzia - UCB), a tumor necrosis factor (TNF) blocker, for treatment of moderate to severe Crohn's disease refractory to conventional treatment. It is the third TNF blocker approved for this...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.